Equal-WT
WhaleScore 2.0
?
LYNX1 CAPITAL MANAGEMENT LP
SAN JUAN PR
Investment Advisor
Hedge Fund
Lynx1 Capital Management is based out of San Juan. Lynx1 Capital Management is a hedge fund with 5 clients and discretionary assets under management (AUM) of $310,306,368 (Form ADV from 2025-03-28). Their last reported 13F filing for Q1 2025 included $279,234,734 in managed 13F securities
and a top 10 holdings concentration of 98.16%. Lynx1 Capital Management's largest holding is GH Research PLC with shares held of 6,443,940. Whalewisdom has at least 16 13F filings, and 39 13G filings
Business Description
The Firm acquired research and research services using client brokerage commissions during its last fiscal year. This included proprietary research from brokers and consultations with industry consultants.
The Firm may direct client brokerage business to brokers that refer prospective investors, creating a conflict of interest. To mitigate this, the Firm will only allocate brokerage business to referring brokers if it aligns with the Firm’s best execution duties. The Lynx1 GP serves as the general partner to certain Funds.
Investment Strategy
The Firm employs various investment strategies, including a long-only equity strategy focused on biotechnology for the Flagship Funds, aiming for attractive, risk-adjusted returns over the long term. This strategy relies on deep fundamental research, scientific expertise, and experience to identify long investments, seeking attractive commercial rewards and managing technical risks. The Firm may also invest opportunistically in securities or transactions that vary from the core strategy of the Flagship Funds.
Future client accounts are expected to pursue various strategies, some similar to the Flagship Funds. The Opportunity Fund focuses on investing in one or more private companies. The Funds' portfolio is expected to be concentrated in the biotechnology industry, which exposes them to risks associated with this sector, including rapid technological advances and product obsolescence. The Funds intend to hold a limited amount of positions at any given time and the Funds may hold relatively large positions in few securities.
Owners
- LYNX1 CAPITAL MANAGEMENT GP LLC - GENERAL PARTNER
- NICHOLS, WESTON, AGNEW - CHIEF INVESTMENT OFFICER, LIMITED PARTNER
- PARTYKA ZAMORA, NATHALI, JOAQUINA - CHIEF COMPLIANCE OFFICER Click on the Ownership/Private Fund Data tab for more details.
Known Email Addresses
(Subscription Required)
Other Contact Information
(Subscription Required)
2025-03-31
Top Buys (13F)
| Name | % Change |
|---|---|
| GHRS GH Research PLC | 12.7% |
| PTGX Protagonist Therapeu | 12.69% |
| CGEM Cullinan Therapeutic | 2.97% |
| DSGN Design Therapeutics | 0.09% |
| ALLO Allogene Therapeutic | -2.9% |
2025-03-31
Top Sells (13F)
| Name | % Change |
|---|---|
| KROS Keros Therapeutics, | 3.23% |
| ALLK Allakos Inc | 1.65% |
| MRUS Merus N.V | 1.28% |
| UPB Upstream Bio Inc | 1% |
| CRBU Caribou Biosciences | 0.41% |
2025-03-31
13F Holdings Summary
| Name | $ Change |
|---|---|
| GHRS GH Research PLC | 25.45% |
| MRUS Merus N.V | 23.65% |
| PTGX Protagonist Therapeu | 12.69% |
| STOK Stoke Therapeutics I | 12.6% |
| CGEM Cullinan Therapeutic | 8.72% |
2025-03-31
13F Activity
| Market Value | $279m, Prior: $267m |
| Inflows (Outflows) as % of Total MV | +18.9199% |
| New Purchases | 2 stocks |
| Added To | 5 stocks |
| Sold out of | 6 stocks |
| Reduced holdings in | 2 stocks |
| Top 10 Holdings % | 98.16% |
| Turnover %[1] | 40% |
| Turnover Alt %[2] | 5.74% |
| Time Held Top 20 | 4.9286 quarters |
| Time Held Top 10 | 4.4 quarters |
| Time Held All | 4.93 quarters |
[1]: Turnover is calculated by taking the # of new holdings (initial purchases) + the # of positions sold out of (not just reduced) divided by the total # of holdings for the quarter.
[2]: Alt Turnover is calculated by taking either the total MV of new purchases or the MV of securities sold, whichever is less, divided by the total MV of the fund.
2025-03-31
13F Sector Allocation Over Time
limited to past 4 quarters. Subscribe to see all available data
2025-03-31
Analysis
Top 20 equal-weighted holdings. Performance numbers calculated through 2025-03-31